Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von María-Alexandra Cañas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Daptomycin, Anti-Bacterial Agents, Staphylococcal Infections, Endocarditis, Bacterial. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Spanish Network for Research in Infectious Diseases.
Abstract (Originalsprache)
Background
Daptomycin is a bactericidal antibiotic, highly effective against MRSA. Linezolid, though bacteriostatic, is effective in MRSA pneumonia and has excellent meningeal penetration. Therefore, the combination of both antibiotics can be required in some patients with disseminated MRSA infections.
Objectives
This study aimed to evaluate the in vitro activity of linezolid plus daptomycin against MRSA and glycopeptide-intermediate Staphylococcus aureus (GISA) strains and to determine the efficacy of linezolid monotherapy administered every 12 h versus every 8 h versus the combination of linezolid-q12h plus daptomycin against MRSA and GISA experimental endocarditis (EE).
Methods
In vitro time-kill studies were performed using standard (105 cfu/L) and high (109 cfu/mL) inoculum of six MRSA strains, including one GISA strain. MRSA-277 and GISA-700788 were selected for the EE model. Animals were treated with linezolid-q12h (600 mg/kg/12 h), linezolid-q8h (600 mg/kg/8 h), daptomycin (6 mg/kg/day) or daptomycin plus linezolid-q12h mimicking human-like serum levels.
Results
Linezolid-q8h and linezolid-q12h showed similar activity in MRSA-277 EE (P = 0.15). Against GISA-700788 endocarditis, linezolid-q8h was more effective than linezolid-q12h (P < 0.001). Daptomycin monotherapy was very effective against MRSA-277 and GISA-700788 EE, sterilizing 70% and 60% of valvular vegetations, respectively. Daptomycin plus linezolid-q12h was similarly effective at 60% and 56%, respectively. This combination showed neither in vitro nor in vivo antagonism, and daptomycin-non-susceptible strains were not recovered.
Conclusions
Increasing linezolid to 600 mg/8 h might be useful as initial treatment in clinical practice. If required, the combination of daptomycin plus linezolid-q12h could be a suitable option in MRSA/GISA bacteraemia/endocarditis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
- Microbiology Service and ISGlobal, Hospital Clinic-University of Barcelona, Barcelona, Spain.
- Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain.
- CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
- Reial Academia de Medicina de Catalunya, Barcelona, Spain.
ORCID-Profile: María-Alexandra Cañas, Cristina García-de-la-Mària, Francesc Marco, Guillermo Cuervo, José M Miró
Förderung
- Instituto de Salud Carlos III
- Ministerio de Economia y Competitividad
- Spanish Network for Research in Infectious Diseases
- Instituto Carlos III
- Pla estratègic de recerca i innovació en salut
- Rio Hortega Research Grant
- Juan Rodés Research Grant
- Institut d'Investigacions Biomèdiques August Pi i Sunyer
Zitieren
APA
Cañas, M. A., García-de-la-Mària, C., García-González, J., Jiménez, M. P., Marco, F., Sarasa, M., Hernández-Meneses, M., Quintana, E., Falces, C., Tolosana, J. M., Vidal, B., Perissinotti, A., Llopis, J., Moreno, A., Cuervo, G., Miró, J. M., & HOSPITAL CLINIC ENDOCARDITIS STUDY GROUP (2025). Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf149
Vancouver
Cañas MA, García-de-la-Mària C, García-González J, Jiménez MP, Marco F, Sarasa M, et al. Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf149
BibTeX
@article{Caas2025,
author = {Cañas, María-Alexandra and García-de-la-Mària, Cristina and García-González, Javier and Jiménez, María Pilar and Marco, Francesc and Sarasa, María and Hernández-Meneses, Marta and Quintana, Eduard and Falces, Carles and Tolosana, José M and Vidal, Barbara and Perissinotti, Andres and Llopis, Jaume and Moreno, Asunción and Cuervo, Guillermo and Miró, José M and HOSPITAL CLINIC ENDOCARDITIS STUDY GROUP, HOSPITAL CLINIC ENDOCARDITIS STUDY GROUP},
title = {Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf149}
}
EUVIMED